Work

ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Year: 2019

Type: article

Abstract: BCR-ABL1 transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with BCR-ABL1 transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed. See related article by Nicolini et al., p. 6606

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-2270

Authors: Dongqing Yan, Anthony D. Pomicter, Thomas O'Hare, Michael W. Deininger

Institutions: University of Utah, Huntsman Cancer Institute

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Leukemia and Lymphoma Society, National Cancer Institute